Prometheus Biosciences to Present at the 40th Annual J.P. Morgan Virtual Healthcare Conference
January 05 2022 - 8:30AM
Prometheus Biosciences, Inc. (Nasdaq: RXDX), a clinical-stage
biotechnology company pioneering a precision medicine approach for
the discovery, development, and commercialization of novel
therapeutic and companion diagnostic products for the treatment of
immune-mediated diseases, today announced that Mark McKenna,
Chairman and CEO, will present a company overview at the 40th
Annual J.P. Morgan Virtual Healthcare Conference on Wednesday,
January 12, at 1:30 p.m. EST.
The presentation will be webcast live on the Events
& Webcasts page on the Investor section of Prometheus’ website
and will be available for 30 days following the presentation. It is
recommended that users connect to Prometheus’ website several
minutes prior to the start of the webcast to ensure a timely
connection.
About Prometheus
BiosciencesPrometheus Biosciences, Inc. is a
clinical-stage biotechnology company pioneering a precision
medicine approach for the discovery, development, and
commercialization of novel therapeutic and companion diagnostic
products for the treatment of immune-mediated diseases. The
Company’s precision medicine platform, Prometheus360™, combines
proprietary machine learning-based analytical approaches with one
of the world’s largest gastrointestinal bioinformatics databases to
identify novel therapeutic targets and develop therapeutic
candidates to engage those targets.
The Company’s lead candidate, PRA023, is an IgG1
humanized monoclonal antibody (mAb) for the treatment of
immune-mediated diseases including Ulcerative colitis (UC), Crohn’s
disease (CD), and the newly identified systemic
sclerosis-associated interstitial lung disease (SSc-ILD). The
Company is currently conducting a Phase 2 trial in UC patients and
a Phase 2a trial in CD patients, each utilizing a proprietary
genetic-based companion diagnostic designed to identify patients
who are predisposed to increased expression of TL1A and therefore
potentially more likely to respond to PRA023. The company also
plans to initiate a Phase 2 clinical trial for PRA023 in SSc-ILD in
the first quarter of 2022.
Prometheus Biosciences
Contact:Noel KurdiVP Investor Relations and
Communications(646) 241-4400nkurdi@prometheusbiosciences.com
Media contact:Juniper PointAmy
Conrad(858) 914-1962media@prometheusbiosciences.com
Prometheus Biosciences (NASDAQ:RXDX)
Historical Stock Chart
From Mar 2024 to Apr 2024
Prometheus Biosciences (NASDAQ:RXDX)
Historical Stock Chart
From Apr 2023 to Apr 2024